We report isoniazid (INH) induced tics in one male patient on hemodialysis at end-stage renal failure. He had pulmonary tuberculosis, accepted isoniazid, rifampin, ethambutol, pyrazinamide and rifampicin. He developed tics on both sides of the face. Surprisingly, he was also found the bilateral symmetrical frontal lobe and dentate nucleus hyperintensities on T2-weighted and T2 FLAIR MR imaging. After excluding other causes, INH induced neurological side effect was suspected so the drug was stopped, pyridoxine was added and hemoperfusion was applicated. Tics disappeared after 1 week.
Introduction
INH is a first-line drug for anti-tuberculosis, and the therapeutic dose rarely causes adverse reactions. However, many scholars had found when there was excessive smoking, drinking or renal failure, the therapeutic dose of INH was easy to cause the central nervous system toxicity [1] [2]. So we report one case of INH induced facial tics at therapeutic dose. frontal lobe and cerebellar dentate nuclei, but no necrotic lesion was found, the vascular and organic neurological causes were excluded, an INH toxicity to brain was suspected (the serum level of INH was not determined in our laboratory).
Case
Then the INH was stopped and pyridoxine in a dose of 80 mg/day was administered. After 4 days, the symptom was improved significantly and INH was re-added to anti-tuberculosis therapy in a lower dose of 200 mg/day. On day 7
after the adjustment of anti-tuberculosis therapy, the tics disappeared completely.
Discussion
It is reported that patients with end stage renal disease have a high incidence of tuberculosis, as well as increased incidence of side effects secondary to anti-tuberculosis agent in treatment of anti-tuberculosis in patient with ESRD [3] .
The mechanism maybe associated with increasing of serum concentration of anti- ity of these agents [4] .
As the first-line drugs for treatment of tuberculosis, INH is well known to have more neurological side effects. Such as headache, insomnia, fatigue, memory loss, illusion, convulsions, and facial tics may be the first reported in cases with ESRD on hemodialysis. It is reported that the neurological side effects of INH is associated with its metabolism style and the ability of competing with pyridoxine [5] .
Those with slow acetylation metabolize INH more slowly than others with fast acetylation, and therefore have higher serum level of INH, which produce more side effects. In addition, the ability of crossing the blood-brain barrier produces higher level of INH in brain [6] . In this reported case, vitamin B6 was not administered until the tics occurred, which may be an import reason causing neurotoxic syndrome. Also, when there was renal dysfunction, the excretion of INH decreased, leading to increased concentration, and low serum albumin, high concentration of creatinine, and urea nitrogen would increase the permeability of blood brain barrier to INH. Meanwhile, INH may inhibit the utilization of pyridoxine, when pyridoxine deficiency, GABA production decreased, leading to excitement, restlessness, and even tics [5] [7] .
Prasant Peter [8] reported that isolated bilateral symmetrical dentate nucleus hyperintensities on T2-weighted and T2 FLAIR MR imaging in a patient with neurological side effects secondary to INH. In this case, we also found the bilateral symmetrical frontal lobe hyperintensities MR imaging. In the present case, all these differentials were ruled out based on the patient's medical history and the results of clinical investigations. Therefore, we concluded that the unusual imaging presentations were a result of INH neurotoxicity.
Another particularly aspect noticed was symptoms and Imaging findings showed in the reported case was not concordance. This indicated damage was greater than Imaging findings.
Conclusion
In conclusion, the possibility of facial tics secondary to INH neurotoxicity should be considered in patients on hemodialysis who undergo anti-tuberculosis treatment. In order to prevent the neurotoxicity associated with INH therapy, treatment with high-dose pyridoxine should be initiated. INH should also be withheld if symptoms of neurotoxicity don't stop or develop. When the patient has renal insufficiency and low immunity, the dose of isoniazid should be reduced.
